US blow for drugs firm

Shares in AstraZeneca tumbled 6% today after a key drug it has developed in the fight against strokes was provisionally rejected by US regulators.

US blow for drugs firm

Shares in AstraZeneca tumbled 6% today after a key drug it has developed in the fight against strokes was provisionally rejected by US regulators.

AstraZeneca was told it needed to provide more data on Exanta amid fears that the blood-thinning drug could cause liver failure in patients over the long term.

You have reached your article limit. Already a subscriber? Sign in

Unlimited access starts here.

Try from only €0.25 a day.

Cancel anytime

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited